P21: SUBSEQUENT ANTI‐MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE‐CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY.

Details

Language :

English

ISSN :

25729241

Volume :

6

Database :

Complementary Index

Journal :

HemaSphere

Publication Type :

Academic Journal

Accession number :

175235231

Full Text :

https://doi.org/10.1097/01.HS9.0000829656.69351.86